Thoma Gebhard, Markert Christian, Lueoend Rainer, Miltz Wolfgang, Spanka Carsten, Bollbuck Birgit, Wolf Romain M, Srinivas Honnappa, Penno Carlos A, Kiffe Michael, Gajewska Monika, Bednarczyk Dallas, Wieczorek Grazyna, Evans Amanda, Beerli Christian, Röhn Till A
Global Discovery Chemistry, Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland.
Chemical Biology & Therapeutics, Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland.
J Med Chem. 2023 Dec 14;66(23):16410-16425. doi: 10.1021/acs.jmedchem.3c01866. Epub 2023 Nov 28.
The discovery of chiral amino alcohols derived from our previously disclosed clinical LTA4H inhibitor is described. In a biochemical assay, their optical antipodes showed similar potencies, which could be rationalized by the cocrystal structures of these compounds bound to LTA4H. Despite comparable stabilities in liver microsomes, they showed distinct in vivo PK properties. Selective -phosphorylation of the ()-enantiomers in blood led to clearance values above the hepatic blood flow, whereas the ()-enantiomers were unaffected and exhibited satisfactory metabolic stabilities in vivo. Introduction of two pyrazole rings led to compound ()- with a more balanced distribution of polarity across the molecule, exhibiting high selectivity and excellent potency in vitro and in vivo. Furthermore, compound ()- showed favorable profiles in 16-week IND-enabling toxicology studies in dogs and rats. Based on allometric scaling and potency in whole blood, compound ()- has the potential for a low oral efficacious dose administered once daily.
本文描述了从我们之前公开的临床LTA4H抑制剂衍生而来的手性氨基醇的发现。在生化测定中,它们的旋光对映体显示出相似的效力,这可以通过这些化合物与LTA4H结合的共晶体结构来解释。尽管在肝微粒体中具有相当的稳定性,但它们在体内表现出不同的PK特性。血液中()-对映体的选择性磷酸化导致清除值高于肝血流量,而()-对映体不受影响,并在体内表现出令人满意的代谢稳定性。引入两个吡唑环导致化合物()-在整个分子中具有更平衡的极性分布,在体外和体内表现出高选择性和优异的效力。此外,化合物()-在犬和大鼠的16周IND支持毒理学研究中显示出良好的特征。基于异速生长标度和全血中的效力,化合物()-有可能每日给药一次的低口服有效剂量。